YAKHAK HOEJI (약학회지)

The Pharmaceutical Society of Korea (대한약학회)
권호 표지

Factors Associated with Fixed Budgets for Pharmaceuticals in European Countries

유럽국가들의 약품비 총액관리제 시행과 관련된 요인 분석 및 시사점

  • Rhee, Jinnie (Health Insurance Policy Research Institute, National Health Insurance Service) ;
  • Shin, Gyeongyeon (College of Pharmacy, Chungang University)
  • 이진이 (국민건강보험공단 건강보험정책연구원) ;
  • 신경연 (중앙대학교 약학대학)
  • Received : 2013.03.26
  • Accepted : 2013.06.13
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

This study examines factors associated with fixed budgets for pharmaceuticals and clawback system for pharmaceutical industry in European countries. We used information from a survey held in 2005~2006 by Austrian Health Institute. Several information including pharmaceutical pricing policies, marketing conditions for pharmaceutical industry and patient' choice of drugs was collected. Five out of twenty five countries in EU were considered as countries with fixed budgets for pharmaceuticals and remaining 20 countries were considered as countries without fixed budget system. Comparisons were made for each information. Countries with fixed budgets for pharmaceuticals were more likely to have internal (or external) reference pricing system and other pricing mechanisms. In addition, they were more likely to permit pharmaceutical industry to be engaged in public advertising and information provision towards patients. They guaranteed patient participation in drug choice decisions. The countries with fixed budgets for pharmaceuticals were more likely to have conditions that enable the fixed budget system to work better compared to those without fixed budget system. Therefore, the study results imply that we need to check whether we have similar conditions to the countries that already have fixed budgets for pharmaceuticals when we want to introduce fixed budget mechanism for pharmaceuticals in Korea in the future.

Keywords

References

  1. 권혜영, 양봉민 : 고정예산제를 활용한 외국의 약제비 관리와 시사점. 보건경제와 정책연구 17 (2011).
  2. Comite Economique des Produits de Sante (CEPS) - Healthcare products pricing committee: Annual Report 2008, Paris (2009).
  3. CEPS : Rapport annuel d'activite 2006, Comite economique des produits de sante, Paris (2007).
  4. Cour des Comptes : La securite sociale, Paris (2004).
  5. Delcroix-Lopes, S. : French Pharmaceutical system: Focus on pricing and reimbursement, PPRI Conference, Vienna (2011).
  6. Durieux, P., Chaix-Couturier, C., Durand-Zaleski, I. and Ravaud, P. : From clinical recommendations to mandatory practice: the introduction of regulatory practice guidelines in the French healthcare system. International Journal of Technology Assessment in Health Care 16, 969 (2000). https://doi.org/10.1017/S0266462300103046
  7. Grandfils, N. : Drug price setting and regulation in France, IRDES, Paris (2008).
  8. Le Pen, C. : The Drug Budget Silo Mentality: The French Case. Value Health 6, S10 (2003). https://doi.org/10.1046/j.1524-4733.6.s1.2.x
  9. OBIG (Osterreichisches Bundesinstitut fur Gesundheitswesen) : Pharmaceutical Pricing and Reimbursement Information - France, Vienna (2008).
  10. Corens, D. : Health Systems in Transition: Belgium Health System review (2007).
  11. Eggermont, M. and Kanavos, P. : Pricing and Reimbursement in Belgium. London School of Economics and Political Science, London (2001).
  12. Gerkens, S. and Merkur, S. : Health Systems in Transition, Belgium Health System Review (2010).
  13. OBIG : Pharmaceutical Pricing and Reimbursement Information - Belgium, Vienna (2008).
  14. Schokkaert, E. and Van de Voorde, C. : Health care reform in Belgium. Health Economics. 16, S25 (2005).
  15. Donatini, A., Rico, A., D'Ambrosio, M. G., Scalzo, A. L., Orzella, L., Cicchetti, A. and Profili, S. : Health Care Systems in Transition: Italy, European Observatory on Health Care Systems, Copenhagen (2001).
  16. Fattore, G. and Jommi, C. : The new pharmaceutical policy in Italy. Health Policy. 46, 21 (1998). https://doi.org/10.1016/S0168-8510(98)00047-5
  17. Folino-Gallo, P., Montilla, S., Bruzzone, M. and Martini, N. : Pricing and reimbursement of pharmaceuticals in Italy. Eur. J. Health Econ. 9, 305 (2008). https://doi.org/10.1007/s10198-008-0114-5
  18. Scalzo, A. L., Donatini, A., Orzella, L., Cicchetti, A., Profili, S. and Maresso, A. : Health Systems in Transition, Italy: Health System Review (2009).
  19. Mapelli, V. and Lucioni, C. : Spending on Pharmaceuticals in Italy: Macro Constraints with Local Autonomy. Value in Health 6, 31 (2003). https://doi.org/10.1046/j.1524-4733.6.s1.4.x
  20. OBIG : Pharmaceutical Pricing and Reimbursement Information - Italy, Vienna (2007).
  21. The Pharma Letter : Italian pharma overspending payback decree "threatens industry collapse", (2004-07-26). available at: http://www.thepharmaletter.com/file/48267/italian-pharma-overspending- payback-decree-threatens-industry-collapse. html.
  22. OBIG/European Commission : Surveying, Assessing and Analysing the Pharmaceutical Sector in the 25 EU Member States, Vienna (2006).
  23. Seiter, A. : Pharmaceutical Pricing and Reimbursement - A Global Perspective, PPRI Conference, Vienna (2011).
  24. Vogler, S. : Pricing and reimbursement of medicines: A European overview, PPRI Conference, Vienna (2011).
  25. Sood, N., De Vroes. H., Gutierrez, I., Lakdawalla, D. N. and Goldman, D. P. : The Effect of Regulation on Pharmaceutical Revenues: Experience In Nineteen Countries. Health Affairs. 28, w125 (2008).
  26. 이의경, 김성옥, 배정윤, 강현하, 김지연 : 약제비 적정화방안이 약국 및 제약업계에 미치는 영향 분석과 정책 대안, 숙명여자대학교/의약품정책연구소 (2007).